# Memorandum

DATE: December 12, 2017

TO: Alexey Khrenov, Ph.D., BLA Committee Chair
Steven Winitsky, M.D., BLA Committee Clinical Reviewer
Pratibha Rana, M.S., BLA Committee RPM

FROM: Anthony Hawkins, M.S., Bioresearch Monitoring Branch
Division of Inspections and Surveillance
Office of Compliance and Biologics Quality

THROUGH: Dennis Cato, Chief, Bioresearch Monitoring Branch

THROUGH: Carrie Mampilly, M.P.H., Director, Division of Inspections and Surveillance

SUBJECT: Bioresearch Monitoring Discipline Review
BLA: STN 125659/0
PRODUCT: Plasminogen (Human)
SPONSOR: Prometic Biotherapeutics, Inc.

REVIEW SUMMARY

One bioresearch monitoring (BIMO) inspection of a U.S. clinical investigator was conducted in support of this Biologics Licensing Application (BLA). Results from the inspection did not reveal substantive problems that impact the data submitted in the BLA.

BACKGROUND

One clinical investigator study site under phase 2/3 Protocol 2002C011G was identified for bioresearch monitoring (BIMO) inspection. The BLA review committee concurred with the proposed site. The site was selected based upon number of enrolled subjects.

The inspection was conducted in accordance with FDA's Compliance Program Guidance Manual (CPGM) 7348.811, Inspection Program for Clinical Investigators. Information submitted in the BLA was compared to source documents at the inspected site. The inspection assignment also included specific questions concerning the clinical study.

Protocol inspected:

> *A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia*

Protocol 2002C011G was conducted at two study sites, Indianapolis, IN, and Oslo, Norway. Protocol 2002C011G is an ongoing study.

INSPECTED STUDY SITE

| Study Site # | Site Name | Location | Form 483 Issued? | Final Inspection Classification |
|---|---|---|---|---|
| 01 | Indiana Hemophilia and Thrombosis Center | Indianapolis, IN | No | NAI |

NAI = No Action Indicated

INSPECTIONAL FINDINGS
Results from the inspection showed no significant findings. The FDA investigator noted a total of 14 screened subjects at the site, with 12 subjects enrolled and treated; there was one screen failure; the other subject decided to not participate in the study. The most recent subject screening occurred on 12/28/2016. Clinical study 2002C011G is still open to enrollment.

SPONSOR/MONITORING ISSUES
No sponsor or monitoring issues were noted.

FINANCIAL DISCLOSURE
The Clinical Investigator Compliance Program (CPGM 7348.811) directs the FDA investigator to ask the clinical investigator if and when he/she disclosed information about his/her financial interests to the sponsor and/or interests of any sub-investigators, spouse(s) and dependent children, as well as if and when the information was updated. Information submitted with the BLA was verified for the inspected clinical investigator.

ADMINISTRATIVE FOLLOW-UP
We issued a letter to the above clinical investigator. Should you have any questions or comments about the contents of this memo or any aspect of Bioresearch Monitoring, please contact me at 240-402-8950.

_____
Anthony Hawkins
Consumer Safety Officer

DISTRIBUTION

Electronic Copies:
Upload to Application Folder in EDR
Alexey Khrenov, BLA Committee Chair
Steven Winitsky, BLA Clinical Reviewer
Pratibha Rana, BLA RPM
Carrie Mampilly
Dennis Cato
Colonious King
cberbimonotification@fda.hhs.gov
Division of Bioresearch Monitoring Operations West (BIMOW)
Corrine Carter, FDA Investigator

Draft: Hawkins: 12/12/2017
Reviewed: Drabick: 12/12/2017
Reviewed: Cato: 12/12/2017